Abstract: Beverages are provided having enhanced colloidal stability using a low calcium sensitive (calcium stable) high acyl gellan gum. The low calcium sensitive high acyl gellan gum has superior suspension performance for colloidal stability compared to other high acyl gellan gums. The low calcium sensitive high acyl gellan gum is prepared by adjusting the pH of a gellan fermentation broth (polymer solution) prior to pasteurization and reducing the pasteurization hold time compared to conventional pH levels and hold times.

Abstract: A low calcium sensitive (calcium stable) high acyl gellan gum is prepared for enhanced colloidal stability in beverages. The low calcium sensitive high acyl gellan gum has superior suspension performance for colloidal stability compared to other high acyl gellan gums. The low calcium sensitive high acyl gellan gum is prepared by adjusting the pH of a gellan fermentation broth (polymer solution) prior to pasteurization and reducing the pasteurization hold time compared to conventional pH levels and hold times.

Abstract: A low calcium sensitive (calcium stable) high acyl gellan gum is prepared for enhanced colloidal stability in beverages. The low calcium sensitive high acyl gellan gum has superior suspension performance for colloidal stability compared to other high acyl gellan gums. The low calcium sensitive high acyl gellan gum is prepared by adjusting the pH of a gellan fermentation broth (polymer solution) prior to pasteurization and reducing the pasteurization hold time compared to conventional pH levels and hold times.

Abstract: A low calcium sensitive (calcium stable) high acyl gellan gum is prepared for enhanced colloidal stability in beverages. The low calcium sensitive high acyl gellan gum has superior suspension performance for colloidal stability compared to other high acyl gellan gums. The low calcium sensitive high acyl gellan gum is prepared by adjusting the pH of a gellan fermentation broth (polymer solution) prior to pasteurization and reducing the pasteurization hold time compared to conventional pH levels and hold times.

Abstract: This disclosure provides for xanthan gum polymer, and methods of making thereof, having enhanced properties such as improved hydration tolerance, hydration rates, and/or viscosity properties, as compared to conventional xanthan gum, while maintaining beneficial xanthan gum properties such as enzyme stability and shear stability. The organism used in the fermentation to produce the disclosed xanthan gum typically is a strain of Xanthomonas campestris pathovar campestris. These and other aspects of the xanthan gum are described.

Abstract: Paint formulations that exhibit improved performance characteristics due to the presence of a combination of a cellulose ether (carboxymethylcellulose and/or hydroxyethylcellulose) and a network building polymer (gellan gum, carrageenan, etc., as examples) as a thickening system therein are provided. Such a combination permits long-term shelf stability of the paint formulation while simultaneously according effective flow, leveling, and other important properties to the final paint formulation. The combination of the cellulose ether and a network building polymer allows for a lower viscosity cellulosic compound to impart the desired rheological behavior therein while also permitting the other desirable characteristics noted above. Such paint compositions also exhibit improved atomization for spray applications with such a thickening system.

Abstract: Paint formulations that exhibit improved performance characteristics due to the presence of a combination of a cellulose ether (carboxymethylcellulose and/or hydroxyethylcellulose) and a network building polymer (gellan gum, carrageenan, etc., as examples) as a thickening system therein are provided. Such a combination permits long-term shelf stability of the paint formulation while simultaneously according effective flow, leveling, and other important properties to the final paint formulation. The combination of the cellulose ether and a network building polymer allows for a lower viscosity cellulosic compound to impart the desired rheological behavior therein while also permitting the other desirable characteristics noted above. Such paint compositions also exhibit improved atomization for spray applications with such a thickening system.

Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment or prior to initial treatment with IGF-1, is at least about 2 standard deviations below normal for a subject of the same age and gender, a blood level of insulin-like growth factor-I that, and at the time of treatment or prior to initial treatment with IGF-1, is below normal mean levels, usually at least about 1 standard deviations below normal mean levels, for age and gender.

Abstract: Films and/or capsules for the delivery of and/or coating of active ingredients are provided. Such edible films and/or capsules comprise particular modified carboxymethylcellulose (CMC) materials either alone or in combination with other types of hydrocolloids or biogums. The utilization of such modified CMC products aids in the production of such films and/or capsules through the availability of larger amounts of base materials with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, flexible, non-tacky, salt tolerant, and quick dissolving edible films and/or capsules be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with cellulosic-based materials. Furthermore, such novel edible films and/or capsules exhibit excellent clarity, retention of actives, and other physical properties (such as tensile strength, elongation, and ability to be cut into various shapes and sizes, etc.

Abstract: Films and/or capsules for the delivery of and/or coating of active ingredients are provided. Such edible films and/or capsules comprise particular modified carboxymethylcellulose (CMC) materials either alone or in combination with other types of hydrocolloids or biogums. The utilization of such modified CMC products aids in the production of such films and/or capsules through the availability of larger amounts of base materials with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, flexible, non-tacky, salt tolerant, and quick dissolving edible films and/or capsules be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with cellulosic-based materials. Furthermore, such novel edible films and/or capsules exhibit excellent clarity, retention of actives, and other physical properties (such as tensile strength, elongation, and ability to be cut into various shapes and sizes, etc.

Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.

Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.

Abstract: The present invention provides standard deviation score (SDS) calculators, which SDS calculators are useful for transforming insulin-like growth factor-1 (IGF-1) concentrations to IGF-1 standard deviation scores. In one embodiment, IGF-1 blood levels are calculated so as to take into account IGFBP-3 blood levels (and, optionally, IGF-2 blood levels) to provide an IGF-1 production rate, which can be used to calculate an IGF-1 production rate SDS. The IGF-1 SDS and IGF-1 production rate SDS are particularly useful in assessing the stimulated rate of IGF-1 production in response to, for example, growth hormone therapy.

Abstract: A low calcium sensitive (calcium stable) high acyl gellan gum is prepared for enhanced colloidal stability in beverages. The low calcium sensitive high acyl gellan gum has superior suspension performance for colloidal stability compared to other high acyl gellan gums. The low calcium sensitive high acyl gellan gum is prepared by adjusting the pH of a gellan fermentation broth (polymer solution) prior to pasteurization and reducing the pasteurization hold time compared to conventional pH levels and hold times.

Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.

Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.

Abstract: Pectin films are treated to alter their dissolution characteristics. More specifically, films can be made to dissolve more quickly by treating the starting pectin with gamma irradiation. Applications of the pectin films include drug delivery and breath films.

Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment or prior to initial treatment with IGF-1, is at least about 2 standard deviations below normal for a subject of the same age and gender, a blood level of insulin-like growth factor-I that, and at the time of treatment or prior to initial treatment with IGF-1, is below normal mean levels, usually at least about 1 standard deviations below normal mean levels, for age and gender.

Abstract: The present invention provides methods and compositions for reducing visceral fat by administering to the subject a therapeutically effective amount of a compound that increases the bioactive serum levels of insulin-like growth factor-1 (IGF-1) in the subject, thereby ameliorating negative effects of visceral obesity. The invention is useful in the treatment, prevention, or amelioration of one or more symptoms of visceral obesity or IGF-1 deficiency related condition, including, for example, cardiovascular disease and the metabolic syndrome.

Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.